Altered Human CYP3A4 Activity Caused by Antley-Bixler Syndrome-Related Variants of NADPH-Cytochrome P450 Oxidoreductase Measured in a Robust In Vitro System

被引:26
|
作者
Moutinho, Daniela [1 ]
Marohnic, Christopher C. [2 ]
Panda, Satya P. [2 ]
Rueff, Jose [1 ]
Masters, Bettie Sue [2 ]
Kranendonk, Michel [1 ]
机构
[1] Univ Nova Lisboa, Ctr Invest Genet Mol Humana, Fac Med Sci, Dept Genet, P-1349008 Lisbon, Portugal
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA
基金
美国国家卫生研究院;
关键词
HUMAN LIVER-MICROSOMES; ESCHERICHIA-COLI; GENETIC-VARIANTS; DRUG-METABOLISM; P-450; REDUCTASE; TESTER STRAIN; MUTATIONS; MODULATION; PHARMACOGENOMICS; STEROIDOGENESIS;
D O I
10.1124/dmd.111.042820
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
NADPH-cytochrome P450 oxidoreductase (CYPOR) variants have been described in patients with perturbed steroidogenesis and sexual differentiation, related to Antley-Bixler syndrome (ABS). It is important to determine the effect of these variants on CYP3A4, the major drug-metabolizing cytochrome P450 (P450) in humans. In this study, 12 CYPOR_ABS variants were separately coexpressed with CYP3A4 in a robust in vitro system to evaluate the effects of these variants on CYP3A4 activity in a milieu that recapitulates the stoichiometry of the mammalian systems. Full-length CYPOR variants were coexpressed with CYP3A4, resulting in relative expression levels comparable to those found in hepatic tissue. Dibenzylfluorescein (DBF), a CYP3A-specific reporter substrate (Biopharm Drug Dispos 24:375-384, 2003), was used to compare the variants and wild-type (WT) CYPOR activities with that of human liver microsomes. CYP3A4, combined with WT CYPOR, demonstrated kinetic parameters (k(cat) and K-m) equal to those for pooled human liver microsomes. CYPOR variants Y181D, Y459H, V492E, L565P, and R616X all demonstrated maximal loss of CYP3A4 catalytic efficiency, whereas R457H and G539R retained similar to 10 and 30% activities, respectively. Conversely, variants P228L, M263V, A287P, and G413S each showed WT-like capacity (k(cat)/K-m), with the A287P variant being formerly reported to exhibit substantially lower catalytic efficiency. In addition, Q153R exhibited 60% of WT CYPOR capacity to support the DBF O-debenzylation reaction, contradicting increased catalytic efficiency (k(cat)/K-m) relative to that for the WT, reported previously. Our data indicate the importance of use of simulated, validated in vitro systems, employing full-length proteins with appropriate stoichiometric incorporation of protein partners, when pharmacogenetic predictions are to be made for P450-mediated biotransformation.
引用
收藏
页码:754 / 760
页数:7
相关论文
共 37 条
  • [31] EFFECT OF USING DIFFERENT ASSAY BUFFERS ON THE ACTIVITY OF RECOMBINANT HUMAN CYP3A4 CO-EXPRESSED IN E. COLI WITH HUMAN NADPH P450 REDUCTASE
    Voice, Michael W.
    DRUG METABOLISM REVIEWS, 2007, 39 : 100 - 101
  • [32] Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2
    Rhodes, Susan P.
    Otten, Jennifer N.
    Hingorani, Gary P.
    Hartley, Dylan P.
    Franklin, Ronald B.
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2011, 63 (03) : 223 - 226
  • [33] In vitro effects and in silico analysis of newly synthetized pyrrole derivatives on the activity of different isoforms of Cytochrome P450 CYP1A2, CYP2D6 and CYP3A4
    Angelov, Borislav
    Mateev, Emilio
    Georgieva, Maya
    Tzankova, Virginia
    Kondeva-Burdina, Magdalena
    PHARMACIA, 2022, 69 (04) : 1013 - 1017
  • [34] Altered CYP19A1 and CYP3A4 Activities Due to Mutations A115V, T142A, Q153R and P284L in the Human P450 Oxidoreductase
    Udhane, Sameer S.
    Parween, Shaheena
    Kagawa, Norio
    Pandey, Amit V.
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [35] In vitro comparative inhibition profiles of major human drug metabolising cytochrome p450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
    Transon, C
    Leemann, T
    Dayer, P
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (03) : 209 - 215
  • [36] Overexpression of cytochrome P450 isoenzyme CYP3A4 and its NADPH-dependent reductase increases sensitivity of human pancreatic cancer cells to novel anticancer 1-nitroacridine, C-1748
    Borowa-Mazgaj, Barbara
    Mroz, Anna
    Skwarska, Anna
    Augustin, Ewa
    Radominska-Pandya, Anna
    Mazerska, Zofia
    DRUG METABOLISM REVIEWS, 2016, 48 : 66 - 66
  • [37] An in-vitro validation study in the field of toxicokinetics and metabolism: Validation of an LC-MS/MS assay for simultaneous assessment of cytochrome P450 activity using cryopreserved human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, CYP2C9 and CYP1A2
    Bourgogne, E.
    Saucez, G.
    Dell'Aiera, S.
    Rosa, M.
    Jacques-hespel, C.
    Gerin, B.
    Chanteux, H.
    Nicolas, J. M.
    TOXICOLOGY LETTERS, 2011, 205 : S153 - S153